Takeda Pharmaceutical Company Limited Stock
Equities
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,926.00 JPY | +1.57% |
|
-3.75% | +1.88% |
| 06-05 | Takeda Books $2.5 Billion Provision Related to Amitiza Antitrust Litigation | DJ |
| 06-02 | FDA declines to approve Cingulate's ADHD treatment over manufacturing issues | RE |
| Capitalization | 7,782B 48.51B 42.13B 38.56B 36.39B 67.6B 4,610B 68.89B 456B 178B 2,236B 182B 178B | P/E ratio 2026 |
46.4x | P/E ratio 2027 * | 35.7x |
|---|---|---|---|---|---|
| Enterprise value | 11,722B 73.07B 63.46B 58.08B 54.81B 102B 6,944B 104B 686B 269B 3,367B 275B 269B | EV / Sales 2026 |
1.14x | EV / Sales 2027 * | 2.53x |
| Free-Float |
99.25% | Yield 2026 |
3.53% | Yield 2027 * | 4.16% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +1.57% | ||
| 1 week | -3.75% | ||
| Current month | -3.75% | ||
| 1 month | -5.97% | ||
| 3 months | -12.52% | ||
| 6 months | +11.70% | ||
| Current year | +1.88% |
| 1 week | 4,710 |  | 5,059 |
| 1 month | 4,710 | | 5,362 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 59 | 2015-03-31 |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 2024-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 2022-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Christophe Weber
BRD | Director/Board Member | 59 | 2014-05-31 |
Andrew Plump
BRD | Director/Board Member | 60 | 2015-05-31 |
| Director/Board Member | 74 | 2016-05-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-26 | Free | Chief Technology Officer | 34,994 | 0.0022% | ||
| 04-26 | Free | Chief Executive Officer | 323,248 | 0.0203% | ||
| 04-26 | Free | Executive/Senior Manager | 72,124 | 0.0045% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.57% | -3.75% | +15.26% | +9.54% | 48.56B | |
| +0.55% | +2.39% | +47.77% | +154.68% | 1,009B | |
| +2.02% | +3.30% | +51.48% | +47.03% | 560B | |
| +1.02% | +4.37% | +21.21% | +66.03% | 401B | |
| +0.77% | -0.67% | +22.19% | +12.23% | 328B | |
| +2.24% | +0.41% | +29.51% | +17.50% | 288B | |
| +1.85% | +0.14% | +22.04% | +30.54% | 272B | |
| +4.43% | -3.11% | -40.46% | -47.48% | 194B | |
| +1.15% | +3.80% | +21.76% | +57.55% | 189B | |
| -0.02% | -3.92% | +16.93% | +66.19% | 160B | |
| Average | +1.56% | +0.65% | +20.77% | +41.38% | 345B | |
| Weighted average by Cap. | +1.35% | +1.87% | +31.02% | +69.26% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 4,531B 28.25B 24.53B 22.45B 21.19B 39.36B 2,684B 40.11B 265B 104B 1,302B 106B 104B | 4,619B 28.79B 25.01B 22.89B 21.6B 40.13B 2,736B 40.89B 270B 106B 1,327B 108B 106B |
| Net income | 174B 1.09B 945M 865M 816M 1.52B 103B 1.54B 10.21B 4B 50.12B 4.09B 4B | 207B 1.29B 1.12B 1.03B 969M 1.8B 123B 1.83B 12.13B 4.75B 59.5B 4.85B 4.75B |
| Net Debt | 3,940B 24.56B 21.33B 19.52B 18.42B 34.22B 2,334B 34.87B 231B 90.26B 1,132B 92.28B 90.27B | 3,882B 24.2B 21.02B 19.23B 18.15B 33.72B 2,300B 34.36B 227B 88.93B 1,115B 90.92B 88.95B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-05 | 4,926.00 ¥ | +1.57% | 4,448,200 |
| 26-06-04 | 4,850.00 ¥ | +2.15% | 4,360,600 |
| 26-06-03 | 4,748.00 ¥ | -2.10% | 5,041,600 |
| 26-06-02 | 4,850.00 ¥ | -0.64% | 5,212,500 |
| 26-06-01 | 4,881.00 ¥ | -4.63% | 6,637,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition